Aledort L - Search Results

1

Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals.

Berger K, O'Rourke RH, Di Minno MND, Batorova A, Kavakli K, Mannucci PM, Schramm W, Bohn RL, Aledort L. Berger K, et al. Among authors: aledort l. Haematologica. 2024 Nov 14. doi: 10.3324/haematol.2024.285647. Online ahead of print. Haematologica. 2024. PMID: 39540229 Free article.

2

Why should we care about quality of life in persons with haemophilia?

Aledort L, Bullinger M, von Mackensen S, Wasserman J, Young NL, Globe D; Health Related Quality of Life Expert Working Group of the International Prophylaxis Study Group. Aledort L, et al. Haemophilia. 2012 May;18(3):e154-7. doi: 10.1111/j.1365-2516.2012.02771.x. Epub 2012 Feb 22. Haemophilia. 2012. PMID: 22356125

3

Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG).

Feldman BM, Funk S, Lundin B, Doria AS, Ljung R, Blanchette V; International Prophylaxis Study Group (IPSG). Feldman BM, et al. Haemophilia. 2008 Jul;14 Suppl 3:162-9. doi: 10.1111/j.1365-2516.2008.01750.x. Haemophilia. 2008. PMID: 18510537 No abstract available.

4

Measuring patient-reported outcomes in haemophilia clinical research.

Globe D, Young NL, Von Mackensen S, Bullinger M, Wasserman J; Healthrelated Quality Of Life Expert Working Group Of The International Prophylaxis Study Group. Globe D, et al. Haemophilia. 2009 Jul;15(4):843-52. doi: 10.1111/j.1365-2516.2008.01961.x. Epub 2009 Apr 7. Haemophilia. 2009. PMID: 19473425 Review.

5

New directions to develop therapies for people with hemophilia.

Gogia P, Tarantino M, Schramm W, Aledort L. Gogia P, et al. Among authors: aledort l. Expert Rev Hematol. 2023 Jun;16(6):417-433. doi: 10.1080/17474086.2023.2184341. Epub 2023 Mar 8. Expert Rev Hematol. 2023. PMID: 36891589 Free article. Review.

6

Are all licensed haemostatic agents for haemophilia therapy accessible to patients?

Berger K, Batorova A, Bohn R, di Minno M, Mannucci PM, Kavakli K, Schramm W, Aledort L; International Prophylaxis Study Group. Berger K, et al. Among authors: aledort l. Haemophilia. 2022 Nov;28(6):e256-e258. doi: 10.1111/hae.14660. Epub 2022 Sep 19. Haemophilia. 2022. PMID: 36122901 No abstract available.

7

In response to WFH guidelines for the management of haemophilia, 3^rd edition: Is there a difference between extended-half-life FVIII products or not?

Berntorp E, Krassova S, Aledort L. Berntorp E, et al. Among authors: aledort l. Haemophilia. 2021 Nov;27(6):e762-e764. doi: 10.1111/hae.14407. Epub 2021 Sep 8. Haemophilia. 2021. PMID: 34498318 No abstract available.

8

Convalescent plasma for administration of passive antibodies against viral agents.

Di Minno G, Mannucci PM, Ironside JW, Perno CF, Gürtler L, Aledort L. Di Minno G, et al. Among authors: aledort l. Haematologica. 2020 Dec 1;105(12):2710-2715. doi: 10.3324/haematol.2020.267427. Haematologica. 2020. PMID: 33256373 Free PMC article. No abstract available.

9

A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.

Aledort L, Milligan S, Watt M, Booth J. Aledort L, et al. J Manag Care Spec Pharm. 2020 Apr;26(4):492-503. doi: 10.18553/jmcp.2020.26.4.492. J Manag Care Spec Pharm. 2020. PMID: 32223610 Free PMC article.

10

Emicizumab in Hemophilia A. Reply.

Aledort LM. Aledort LM. N Engl J Med. 2020 Feb 20;382(8):786. doi: 10.1056/NEJMc1916299. N Engl J Med. 2020. PMID: 32074442 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

330 results

Search Page

Filters